Author(s):
M. Chinna Eswaraiah, S. Jaya
Email(s):
jayamay24@gmail.com
DOI:
10.5958/0974-360X.2020.00398.4 
Address:
M. Chinna Eswaraiah, S. Jaya*
Department of Pharmaceutics, Anurag Pharmacy College, Ananthagiri, Kodad, Suryapet-508206, Telangana, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 5,
Year - 2020
ABSTRACT:
Telmisartan is an angiotensin II type -1 receptor antagonist, used in the treatment of essential hypertension. Telmisartan belongs to class II under biopharmaceutical classification system, characterized by low solubility and high permeability. Oral absorption of Telmisartan is dissolution rate limited and it requires enhancement of solubility and dissolution. The main objective of the present study is to increase the solubility and dissolution rate of telmisartan through solid dispersion technology using various concentrations of water soluble carriers such as poly vinyl pyrrolidone, polyethylene glycol 4000 and poloxomer 407. Solid dispersions were prepared by solvent evaporation technique using methanol as solvent. The enhancement of dissolution rate depends on the nature and concentration of the carrier. The order of increasing dissolution rate with water soluble carriers was poloxomer 407 > polyethylene glycol 4000 > polyvinyl pyrrolidone. Increasing dissolution may be due to the reduced particle size of the drug, enhanced wettability of the drug by hydrophilic carriers. The formulations were evaluated by fourier transform infrared spectroscopy. Telmisartan tablets formulated employing selected solid dispersions gave higher dissolution than the plain tablets.
Cite this article:
M. Chinna Eswaraiah, S. Jaya. Enhancement of Dissolution Rate of Telmisartan by Solid Dispersion Technique. Research J. Pharm. and Tech 2020; 13(5): 2217-2220. doi: 10.5958/0974-360X.2020.00398.4
Cite(Electronic):
M. Chinna Eswaraiah, S. Jaya. Enhancement of Dissolution Rate of Telmisartan by Solid Dispersion Technique. Research J. Pharm. and Tech 2020; 13(5): 2217-2220. doi: 10.5958/0974-360X.2020.00398.4 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-5-28
REFERENCES:
1. Jaya.S, Chowdary KPR and Rajeswara RP. Effect of superdisintegrants and solubilizers on the dissolution rate and dissolution efficiency of ritonavir tablets. Int Res J Pharm and Appl Sci 2012; 2 (5): 224-9.
2. Janika G, Sadhan K and Sandeep A. Enhancement of dissolution of valsartan by surface solid dispersion technique. J Pharm Res 2012; 5 (8): 4147-51.
3. Aftab M and Pralhad T. Enhancement of dissolution profile by solid dispersion technique. AAPS PharmSciTech 2006:7(3):E1-E6.
4. Jaya S, Chowdary KPR and Rajeswara RP. Formulation development of ritonavir tablets by solid dispersion technologies. Int J Pharm and therapeutics 2013; 4(1):51-8.
5. Kurtz T and Pravenec M. Antidiabetic mechanisms of angiotensin II converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the rennin angiotensin system. Journal of hypertension 2014; 22(12) 2253-61.
6. Sucheta B, Dyandevi M, Mithun VK and Rajendra D. solubility enhancement of antihypertensive agent by solid dispersion technique. Int J Pharm and life sciences 2011; 2(8):791-6.
7. Thirupati A, Sonia G, Sravanthi RP, Mallika A, Sujatha D and Sunitha S. Enhancement of dissolution and bioavailability of poorly soluble telmisartan: Designing modified cyclodextrin inclusion complexes. J of Chemical and Pharma Res 2015; 7(10): 164-74.
8. Jaya S and Amala V. Formulation and invitro evaluation of oral disintegrating tablets of amlodipine besylate. Int J Applied Pharm 2019; 11(1): 49-54.
9. Chinna Eswaraiah M and Jaya S. Formulation and invitro evaluation of metformin hydrochloride sustained release tablets. Journal of drug delivery and therapeutics 2019; 9(4):24-29.
10. Kothawade SN, Kadam NR, Aragade PD and Baheti DG. Formulation and characterization of telmisartan solid dispersions. Int J Pharm Tech Res 2010; 2(1): 341-7.
11. Lakshmanarao P, Chowdary KPR and Prasad SVUM. Optimization of Telmisartan tablet formulation by 2 3 factorial design employing β cyclodextrin, primojel and tween 80. Int J Pharm Sci and Res 2017; 8(3):1178-83.